These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 17714734

  • 1. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
    Tang ZY, Wu YL, Gao SL, Shen HW.
    J Surg Res; 2008 Mar; 145(1):111-23. PubMed ID: 17714734
    [Abstract] [Full Text] [Related]

  • 2. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
    Wissniowski TT, Meister S, Hahn EG, Kalden JR, Voll R, Ocker M.
    Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
    [Abstract] [Full Text] [Related]

  • 3. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
    Denlinger CE, Rundall BK, Keller MD, Jones DR.
    Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
    [Abstract] [Full Text] [Related]

  • 4. Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1.
    Guo Q, Chen Y, Wu Y.
    Tumori; 2009 Oct; 95(6):796-803. PubMed ID: 20210246
    [Abstract] [Full Text] [Related]

  • 5. Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.
    Chandler NM, Canete JJ, Callery MP.
    J Gastrointest Surg; 2004 Dec; 8(8):1072-8. PubMed ID: 15585396
    [Abstract] [Full Text] [Related]

  • 6. Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells.
    Torres C, Linares A, Alejandre MJ, Palomino-Morales RJ, Delgado JR, Perales S.
    Pancreas; 2016 Feb; 45(2):269-80. PubMed ID: 26495790
    [Abstract] [Full Text] [Related]

  • 7. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
    Gao CC, Xu XL, Li F, Gong BG, Liu S, Cui YQ, Sun HC, Xu PY, Zheng YM, Jiang H.
    Tumour Biol; 2016 Jun; 37(6):7555-64. PubMed ID: 26684804
    [Abstract] [Full Text] [Related]

  • 8. pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.
    Wang M, Lu X, Dong X, Hao F, Liu Z, Ni G, Chen D.
    World J Surg Oncol; 2015 Feb 21; 13():66. PubMed ID: 25880226
    [Abstract] [Full Text] [Related]

  • 9. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
    Izetti P, Hautefeuille A, Abujamra AL, de Farias CB, Giacomazzi J, Alemar B, Lenz G, Roesler R, Schwartsmann G, Osvaldt AB, Hainaut P, Ashton-Prolla P.
    Invest New Drugs; 2014 Oct 21; 32(5):783-94. PubMed ID: 24838627
    [Abstract] [Full Text] [Related]

  • 10. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
    Lee JK, Ryu JK, Yang KY, Woo SM, Park JK, Yoon WJ, Lee SH, Jeong KS, Kim YT, Yoon YB.
    Pancreas; 2011 Aug 21; 40(6):966-73. PubMed ID: 21487323
    [Abstract] [Full Text] [Related]

  • 11. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
    Bold RJ, Virudachalam S, McConkey DJ.
    J Surg Res; 2001 Sep 21; 100(1):11-7. PubMed ID: 11516199
    [Abstract] [Full Text] [Related]

  • 12. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets.
    Zhang W, Chen H, Liu DL, Li H, Luo J, Zhang JH, Li Y, Chen KJ, Tong HF, Lin SZ.
    Int J Oncol; 2013 Apr 21; 42(4):1189-96. PubMed ID: 23440366
    [Abstract] [Full Text] [Related]

  • 13. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H.
    Cancer Biol Ther; 2010 Jun 01; 9(11):936-44. PubMed ID: 20418664
    [Abstract] [Full Text] [Related]

  • 14. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ, Higginbottom K, Jüliger S, Maharaj L, Allen P, Schenkein D, Lister TA, Joel SP.
    Cancer Res; 2007 Mar 15; 67(6):2783-90. PubMed ID: 17363600
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
    Chen D, Niu M, Jiao X, Zhang K, Liang J, Zhang D.
    Int J Mol Sci; 2012 Mar 15; 13(1):1186-1208. PubMed ID: 22312312
    [Abstract] [Full Text] [Related]

  • 16. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
    Fahy BN, Schlieman MG, Virudachalam S, Bold RJ.
    J Surg Res; 2003 Jul 15; 113(1):88-95. PubMed ID: 12943815
    [Abstract] [Full Text] [Related]

  • 17. Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
    Märten A, Zeiss N, Serba S, Mehrle S, von Lilienfeld-Toal M, Schmidt J.
    Mol Cancer Ther; 2008 Nov 15; 7(11):3624-31. PubMed ID: 19001444
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
    Vaziri SA, Grabowski DR, Hill J, Rybicki LR, Burk R, Bukowski RM, Ganapathi MK, Ganapathi R.
    Anticancer Res; 2009 Aug 15; 29(8):2961-9. PubMed ID: 19661301
    [Abstract] [Full Text] [Related]

  • 19. Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.
    Chien W, Ding LW, Sun QY, Torres-Fernandez LA, Tan SZ, Xiao J, Lim SL, Garg M, Lee KL, Kitajima S, Takao S, Leong WZ, Sun H, Tokatly I, Poellinger L, Gery S, Koeffler PH.
    Oncotarget; 2014 Jul 15; 5(13):4881-94. PubMed ID: 24952679
    [Abstract] [Full Text] [Related]

  • 20. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N.
    Invest Ophthalmol Vis Sci; 2007 Oct 15; 48(10):4706-19. PubMed ID: 17898295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.